15th week of 2021 patent applcation highlights part 7 |
Patent application number | Title | Published |
20210106525 | FORMULATIONS FOR GASTROINTESTINAL DELIVERY OF OLIGONUCLEOTIDES - Compositions and methods for effective delivery of oligonucleotide therapeutics, and in particular locked nucleic acid (AON)-containing gapmers, into the gastrointestinal (GI) tract are provided. | 2021-04-15 |
20210106526 | MATRIX BOUND VESICLES (MBVS) CONTAINING IL-33 AND THEIR USE - Methods are disclosed for treating a subject with a disorder, such as, but not limited to, a) fibrosis of an organ or tissue; b) solid organ transplant rejection; or c) a cardiac disease that is not myocardial infarction or myocardial ischemia. These methods include selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles contain interleukin (IL)-33 and comprise lysyl oxidase, and wherein the nanovesicles a) do not express CD63 or CD81, or b) are CD63 | 2021-04-15 |
20210106527 | COMPOSITIONS, METHODS AND USES OF MESSENGER RNA - The present invention provides, among other things, methods and compositions for cancer treatment. The methods and compositions disclosed herein are particularly effective in reducing the size/volume of a tumor and inhibiting tumor growth. | 2021-04-15 |
20210106528 | COMBINED PHARMACEUTICAL FORMULATION COMPRISING GEMCITABINE-CONTAINING LIPOSOME COMPOSITION AND IMMUNE CHECKPOINT INHIBITOR - An object of the present invention is to provide a combined pharmaceutical formulation obtained by combining a liposome composition and an immune checkpoint inhibitor, in which gemcitabine is encapsulated in a dissolved state in liposomes in the liposome composition. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes liposomes each having an inner water phase, and an aqueous solution constituting an outer water phase and having the liposomes dispersed therein, gemcitabine is encapsulated in a dissolved state in the liposomes, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially. | 2021-04-15 |
20210106529 | NANOLIPOSOME-MICROBUBBLE CONJUGATE INCLUDING DRUG FOR HAIR LOSS TREATMENT ENCAPSULATED IN NANOLIPOSOME AND COMPOSITION FOR ALLEVIATING OR TREATING HAIR LOSS CONTAINING SAME - Provided are a nanoliposome-microbubble conjugate in which a drug for hair loss treatment such as finasteride, minoxidil, dutasteride, etc. is encapsulated in a nanoliposome and a composition for alleviating or treating hair loss containing the same. Since an orally administered agent such as finasteride, currently useful as a drug for hair loss treatment, causes side effects, drug delivery through scalp application is most desirable, but the drug is not delivered to hair follicle cells through scalp application alone. Since a drug for hair loss treatment useful as an external preparation for skin causes various side effects, the concentration thereof that is used needs to be further lowered. The above nanoliposome-microbubble conjugate is capable of increasing the delivery efficiency of a drug for hair loss treatment at a low concentration, and is thus very effective at treating androgenic alopecia. | 2021-04-15 |
20210106530 | HIGH-EFFICIENCY ENCAPSULATION OF HYDROPHILIC COMPOUNDS IN UNILAMELLAR LIPOSOMES - The present invention relates to high-efficiency encapsulation of hydrophilic substances in the hydrophilic space of unilamellar liposomes. High-efficiency encapsulation is achieved by the use of a polyhydric alcohol selected from propylene glycol or glycerine for dissolving the hydrophobic compounds forming the lipid bilayer of the liposomes. The invention provides unilamellar liposomes (UL) as well as a method for preparing same by way of low temperature extrusion. The invention also relates to use of these UL in the manufacturing of a medicament, a cosmetic product, a food additive or a disinfectant. | 2021-04-15 |
20210106531 | HYDROPHILIC/HYDROPHOBIC PHARMACEUTICAL COMPOSITION AND METHOD OF ITS PRODUCTION AND USE - A method of producing a composition in powder form involves the following steps (a) to (c):
| 2021-04-15 |
20210106532 | INDIGENOUS CBD ORAL DOSAGE FORMS - The present invention is a cannabidiol oral dosage form including predominantly or exclusively hemp pomace, compounded as a tablet or formulated within a capsule without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture and the optional presence of fungal or bacterial probiotics introduced prior to or during dosage form manufacturing, and with or without fermentation of the hemp pomace prior to the dosage form manufacturing process. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG) in a ratio of 30:1 up to 120:1 to hallucinogenic cannabinoids (THC). | 2021-04-15 |
20210106533 | INDIGENOUS AND IMPROVED BACTERIALLY FERMENTED CBD, CBG AND RELATED CANNABINOID ORAL DOSAGE FORMS - The present invention is a cannabidiol oral dosage form including predominantly or exclusively bacterially fermented hemp pomace, compounded as a tablet or formulated within a capsule generally without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG, etc.) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC). | 2021-04-15 |
20210106534 | Disintegrating Oral Tablet Suitable For Active Pharmaceutical Ingredients - The invention relates to a disintegrating oral tablet suitable for active pharmaceutical ingredients comprising a population of particles and at least one flavor ingredient, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and | 2021-04-15 |
20210106535 | NATURAL AND/OR ORGANIC DISINTEGRANT PRE-MIXES FOR (ORAL) SOLID DOSAGE FORMS - Natural disintegrant pre-mixes which are useful for formulating solid dosage forms for oral administration of drugs, vitamins, food supplements, etc. The composition comprises a blend about 20% to about 90% by weight of | 2021-04-15 |
20210106536 | DRUG DELIVERY AGENTS FOR PREVENTION OR TREATMENT OF PULMONARY DISEASE - Provided is a lung disease drug delivery carrier, in which the carrier includes a disc particle made of polylactide-co-glycolide (PLGA), the disc particle contains therein a drug, the carrier delivers and/or releases the drug therein into a lung, and the disc particle has a size of 1 μm to 5 μm. | 2021-04-15 |
20210106537 | EXTENDED RELEASE MULTIPARTICULATES OF RANOLAZINE - The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled onto soft foods or liquids for oral administration. Further, the multiparticulate composition is bioequivalent to the marketed extended release tablet. It further relates to a process of preparation of said multiparticulate composition and method of treatment of patients suffering from angina by administering said composition. | 2021-04-15 |
20210106538 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS - The present invention relates to nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings). | 2021-04-15 |
20210106539 | DELIVERY OF DRUG NANOPARTICLES AND METHODS OF USE THEREOF - A hydrophobic topical skin composition is disclosed. The composition includes greater than 50% w/w of the composition of a continuous hydrophobic carrier, 5-24% w/w of one or more volatile silicone fluids, and 0.1 to 5% w/w of the composition of a plurality of taxane nanoparticles, wherein the mean particle size (number) of the taxane nanoparticles is from 0.1 microns to 1.5 microns, and wherein the taxane nanoparticles are crystalline nanoparticles or a combination of amorphous and crystalline nanoparticles. | 2021-04-15 |
20210106540 | TRANSDERMAL DELIVERY OF CANNABIDIOL - Provided is a transdermal drug delivery system comprising cannabidiol, or a cannabidiol salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and/or prevention of pain and/or inflammation. | 2021-04-15 |
20210106541 | NATURAL COMBINATION PRODUCTS AND METHODS FOR REGULATION OF TOTAL BLOOD CHOLESTEROL - This invention relates to compositions and methods relating a combination of naturally-occurring active ingredients, including active agents unrelated to statins, useful for the regulation total blood cholesterol. The inventive combination of active ingredients, including policosanol, mevinolic acid from dry yeast extract of red rice, dry extract of | 2021-04-15 |
20210106542 | COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION - Inhibition of aggregation of superactivated platelets, blocking of activation of coagulation cascade, treatment of primary open-angle glaucoma, and treatment of microvascular diseases is effected by co-administration of a stilbene, a flavonol, and a μ-opioid receptor antagonist. | 2021-04-15 |
20210106543 | CURCUMINOID COMPOSITION FOR THERAPEUTIC MANAGEMENT OF METABOLIC SYNDROME - The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals. | 2021-04-15 |
20210106544 | CURCUMINOID COMPOSITION AND ITS THERAPEUTIC POTENTIAL IN MANAGING LUNG FIBROSIS - The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis. | 2021-04-15 |
20210106545 | Methods For The Treatment Of Depression - The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations). | 2021-04-15 |
20210106546 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-04-15 |
20210106547 | Managing Cardiovascular Conditions Associated with Kidney Disease - This disclosure relates to managing cardiovascular diseases and conditions associated with kidney disease. In certain embodiments, this disclosure relates to methods of treating or preventing a cardiovascular disease or condition comprising administering an effective amount of a urea transporter inhibitor to a subject in need thereof. In certain embodiments, the subject is diagnosed with kidney disease. In certain embodiments, the subject is diagnosed with uremic cardiomyopathy. In certain embodiments, the urea transporter inhibitor is N,N′-dimethylthiourea (DMTU), prodrug, derivative, or salt thereof. | 2021-04-15 |
20210106548 | ACETYL-LEUCINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION - The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject. | 2021-04-15 |
20210106549 | PHARMACEUTICAL COMPOSITIONS AND METHODS - Pharmaceutical compositions and kits including an alkylester of α-methyl-DL-tyrosine (or salt thereof), for example, α-methyl-DL-tyrosine methyl ester hydrochloride, are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of an alkylester of α-methyl-DL-tyrosine (or salt thereof), for example, α-methyl-DL-tyrosine methyl ester hydrochloride, to the subject in need thereof. | 2021-04-15 |
20210106550 | COMPOSITIONS FOR PREVENTING OR TREATING COGNITIVE IMPAIRMENT-RELATED DISEASE COMPRISING MUMEFURAL - The present invention relates to a composition for preventing or treating a cognitive impairment-related disease, which includes mumefural, and more particularly, to a pharmaceutical composition; a health functional food composition; and a feed composition respectively for preventing or treating a cognitive impairment-related disease; a health functional food composition for enhancing learning ability, cognitive function, or memory, each composition including mumefural or an acceptable salt thereof as an active ingredient; and a method of treating a cognitive impairment-related disease using the pharmaceutical composition. | 2021-04-15 |
20210106551 | LIPIDIC FURAN, PYRROLE, AND THIOPHENE COMPOUNDS FOR USE IN THE TREATMENT OF ATROPHIC VAGINITIS - Provided herein are lipidic furan, pyrrole, and thiophene compounds, compositions, and methods using such compounds and compositions for the treatment of atrophic vaginitis. Specifically, the invention includes administering an effective amount of a compound of Formula I, I′, or I″, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from atrophic vaginitis. | 2021-04-15 |
20210106552 | METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER USING SALVIANOLIC ACID B - The present disclosure provides methods related to treating triple-negative breast cancer (TNBC) in a mammal by administering salvianolic acid B (or a salt or solvate thereof) to promote ceramide-mediated apoptosis. In one form, the ceramide-mediated apoptosis of TNBC cells occurs by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in the subject through the use of an effective amount of salvianolic acid B. In another aspect, salvianolic acid B or its pharmaceutically acceptable salt or solvate is used as a medicament or in the manufacture of a medicament for treating TNBC. | 2021-04-15 |
20210106553 | COMPOSITIONS AND METHODS FOR TREATING AN INFECTION - The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin. | 2021-04-15 |
20210106554 | SELF-EMULSIFYING ANHYDROUS INTRADERMAL DEPOT GEL - The present invention relates to compositions and methods to solubilize poorly water-soluble medicaments using a self-emulsifying, anhydrous gel (SEAG), which then forms an intradermal depot when absorbed. The gel preferably comprises a mixture of propylene glycol, glycerin, ethoxy diglycol, hydroxypropylcellulose, butylated hydroxytoluene, caprylic acid triglyceride and edetate disodium, and may further include an oral-based, bioadhesive paste, which allows the gel to adhere mucosally. The SEAG may further contain a solubilizer such as Kolliphor HS15. | 2021-04-15 |
20210106555 | PHYTOCANNABINOID FORMULATIONS AND METHODS FOR EXTRACTION - A phytocannabinoid formulation comprises an amount of at least about 90 percent by weight of one or more phytocannabinoid. The phytocannabinoid formulation further comprises an amount of at least about 0.1 percent by weight of a plurality of lipophilic molecules including at least one saturated straight chain C | 2021-04-15 |
20210106556 | COMPLETE ANIMAL FOOD HAVING CANNABINOIDS IN TRACE CONCENTRATIONS TO AVOID TOXICITY - A nutritionally complete animal food including, vitamins, and minerals to sustain the animal's health and wellness. The one or more ingredients containing cannabinoids added to the nutritionally complete animal food at the time of manufacturing. These cannabinoids are selected from the group consisting of Cannabichromenic acid (CBCA), Cannabidiolic acid (CBDA), Cannabidivarinic acid (CBDVA), Cannabigerolic acid (CBGA), Cannabinolic acid (CBNA), Δ9-Tetrahydrocannabinolic acid (THCA),Tetrahydrocannabinolic acid (THCVA) and combinations thereof. The concentrations of each of the cannabinoids are each less than 100 parts per million (ppm) in the at least one ingredient. In an alternate embodiment, the one or more ingredients have cannabinoids include in an aggregate concentration of less than 100 parts per million (ppm). | 2021-04-15 |
20210106557 | Method for prevention and treatment of Diabetic Kidney Disease - A method for delaying the progression or preventing Diabetic Kidney Disease by administering to a subject in need a composition containing a therapeutically effective amount of a hyaluronan synthesis inhibitor such as 4-Methylumbelliferone. | 2021-04-15 |
20210106558 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEBIVOLOL - The present invention relates to pharmaceutical compositions comprising the selective beta 1 (B1)-receptor blocker nebivolol and/or a pharmaceutically acceptable salt thereof and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention is useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith. | 2021-04-15 |
20210106559 | COMPOUND ANTIOXIDANT PREPARATION FOR REDUCING THE NUMBER OF SOMATIC CELLS IN A LIVESTOCK ANIMAL AND A PREPARATION METHOD AND APPLICATION THEREOF - Provided are an antioxidant complex for reducing the number of somatic cells in a livestock animal and a preparation method and application thereof. Active components of the preparation are melatonin (MT) having a centration of 2-30 g/L and vitamin C having a concentration of 1-14.3 g/L. The antioxidant complex provided in the present invention can effectively reduce the number of somatic cells in a diary cow and improve milk quality. | 2021-04-15 |
20210106560 | DULOXETINE SPRINKLES - The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms. | 2021-04-15 |
20210106561 | STABILIZED STATIN FORMULATIONS - The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same. | 2021-04-15 |
20210106562 | USE OF MELATONIN FOR THE TREATMENT OF TUMOURS - The present invention relates to the use of melatonin for the preparation of a pharmaceutical composition suitable for intratumoral administration for the treatment of tumors. This composition comprises high concentrations of melatonin, melatonin derivatives or metabolites, such that melatonin exerts an oxidizing effect, increasing the production of free radicals and activating cell death. | 2021-04-15 |
20210106563 | PHARMACEUTICAL COMPOSITION COMPRISING ELUXADOLINE, PROCESS OF PREPARATION AND USE THEREOF - The present invention relates to oral pharmaceutical compositions comprising eluxadoline or a prodrug or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, and process for the preparation thereof and administration of such compositions for irritable bowel syndrome (IBS-D). | 2021-04-15 |
20210106564 | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS - A method is described for the prophylaxis or treatment of hypertension in a cat in need of such treatment. The method includes administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to the cat, where the therapeutically effective amount of the sartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of the sartan for a first period of time during the treatment period is 1.0 to 5.0 mg/kg of body weight, and the daily dosage amount of the sartan is decreased for a second period of time subsequent the first period of time during the treatment period. | 2021-04-15 |
20210106565 | NOVEL USE OF BIOTIN AND NATURAL ESSENTIAL OILS FOR BOVINE ANIMALS FOR THE PREVENTION AND TREATMENT OF KETOSIS - Methods to prevent ketosis or minimize the effects of ketosis in ruminant animals are provided. This methods include feeding to the animal biotin in combination with a mixture of at least two essential oil compounds selected from the group consisting of thymol, eugenol, meta-cresol, vaniline and guajacol. The methods usefully prevent and/or inhibit ketosis of calving ruminant animals and the subsequent need for veterinary treatment. In a preferred embodiment of a feeding concept for dairy cattle, especially calving dairy cattle, biotin is used in an amount sufficient to provide a daily dosage of 10 mg to 20 mg per head to which it is to be administered. It is at present contemplated that the essential oils are administered in amounts (total dosage ranges of essential oils) of 1 to 1.5 g per head per day. | 2021-04-15 |
20210106566 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY - The present invention provides in one embodiment a pharmaceutical composition for treating and/or preventing peripheral neuropathy or spinal cord injury comprising zonisamide or an alkali metal salt thereof as an active ingredient. | 2021-04-15 |
20210106567 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO - Described herein are compositions and methods for treating cancer in a subject. The compositions include selective NF-κB inhibitor inhibitors. The methods include inhibiting the binding of CARP-1 with NEMO. | 2021-04-15 |
20210106568 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS - The present disclosure provides, inter alia, Compounds of Formula (I) | 2021-04-15 |
20210106569 | OMIDENEPAG COMBINATION - Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining omidenepag and ripasudil or netarsudil, each complement and/or enhances the intraocular pressure lowering effect. As the form of administration, they may be administered concomitantly or may be administered as a combination drug. | 2021-04-15 |
20210106570 | Treatment of Debilitating Fatigue - The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS), fibromyalgia (FM) and depression, as well as of combinations thereof. Related treatment methods, pharmaceutical compositions and combination kits are also disclosed. | 2021-04-15 |
20210106571 | ISOTHIOCYANATE-ANDROGEN RECEPTOR INHIBITOR CONJUGATES FOR APOPTOSIS AND/OR FERROPTOSIS INDUCTION IN CANCER CELLS - Isothiocyanate (ITC)-androgen receptor (AR) inhibitor conjugates for apoptosis induction in cancer cells are described. The conjugates can have electrophilicity blocked with an agent such as N-acetyl cysteine. When administered in combination with a glutathione (GSH)-depleting agent, the conjugates result in ferroptosis of cancer cells. | 2021-04-15 |
20210106572 | USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION - The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject. | 2021-04-15 |
20210106573 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS - Disclosed herein are compositions and methods for treating a sigma-2 receptor-mediated condition or disorder, including treating one or more symptoms of a sigma-2 receptor-mediated condition or disorder. | 2021-04-15 |
20210106574 | Methods of Treating Cancer - The present invention provides methods of treatment of cancer patients having deficiency in at least one non-BRCA1/2 gene involved in the homologous recombination repair (HRR) pathway with a poly(ADP-ribose) polymerase (PARP) inhibitor such as niraparib. In particular, cancer patients having a deficiency in at least one gene selected from the group consisting of BRCA1, BRCA2, ATM, ATR, BAP1, BARD1, BLM, BRIP1, MRE11A, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, XRCC2, TP53, or RBI can benefit from treatment with niraparib. | 2021-04-15 |
20210106575 | METHOD OF TREATMENT OF SCHIZOPHRENIA - The invention relates generally to improvements in the treatment of psychotic symptoms, and more particularly, to improvements in the identification of an individual or a population of individuals for whom treatment with iloperidone, an iloperidone metabolite, or pharmaceutically-acceptable salts thereof may provide a particular benefit in treating an individual's psychotic symptoms based on the individual's genotype at the PPEF2 locus. | 2021-04-15 |
20210106576 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING PSORIASIS - Compounds and pharmaceutical compositions for use in the treatment of psoriasis are disclosed. Preferred compounds have demonstrated efficacy in reducing skin scaling, erythema and skin thickness in the mouse model of Aldara-induced psoriasis. | 2021-04-15 |
20210106577 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS - Methods of improving visual endpoints related to retina-associated disease with CCR3 modulating agents are provided. An example of such an endpoint is visual acuity. Retina-associated diseases upon which visual acuity and other visual endpoints may be improved include retinopathy of prematurity, age-related macular degeneration, central retinal vein occlusion, and diabetic retinopathy. | 2021-04-15 |
20210106578 | METHOD OF TREATING DISORDERS ASSOCIATED WITH CHRONIC INFLAMMATION - In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS). | 2021-04-15 |
20210106579 | AMELIORATION OF COGNITIVE AND MOTOR DEFICITS ASSOCIATED WITH ALZHEIMER'S - Cognitive and/or motor deficiencies associated with Alzheimer's are treated using 2-amino substituted nicotinamides on their pharmaceutically acceptable salts. | 2021-04-15 |
20210106580 | COMBINATION THERAPY - The present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The present invention also provides methods for treating cancer in a human in need thereof, the methods comprising administering to the human a combination of a Type I PRMT inhibitor and a Type II PRMT inhibitor, together with at least one of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent, thereby treating the cancer in the human. The present invention further provide a pharmaceutical composition comprising a therapeutically effective amount of a Type I PRMT inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a Type II PRMT inhibitor. | 2021-04-15 |
20210106581 | Treatment Of Liver Diseases - Methods of treating non-alcoholic steatohepatisis (NASH), non-alcoholic fatty liver disease (NAFLD), fatty acid liver disease (FALD), alcoholic liver disease, and/or liver fibrosis in a mammal by administering a lyn kinase activator are provided herein. | 2021-04-15 |
20210106582 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES - The present invention relates to compounds useful in the prophylaxis and/or treatment of one or more fibrotic diseases. In particular, the compounds of the invention antagonize GPR84, a G-protein-coupled receptor. The present invention also provides pharmaceutical compositions comprising the compounds for use and methods for the prophylaxis and/or treatment of one or more fibrotic diseases by administering said compound. | 2021-04-15 |
20210106583 | METHODS OF TREATING PEMPHIGUS BY ADMINISTERING (R)-2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1- -YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-- 2-ENENITRILE - Disclosed herein are methods for treating pemphigus in a human patient in need thereof comprising administering to the human patient a dose of at least 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) once a day (QD) or twice a day (BID). | 2021-04-15 |
20210106584 | METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA BY ADMINISTERING (R)-2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1- -YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-- 2-ENENITRILE - Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising at least one compound chosen from PRN1008 and pharmaceutically acceptable salts thereof are also disclosed. | 2021-04-15 |
20210106585 | NEW TREATMENT - The invention provides a compound for use in treating or preventing a disease or condition selected from cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, mild pulmonary disease, bronchitis, bronchiectasis, idiopathic bronchiectasis, allergic bronchopulmonary aspergillosis, sinusitis, rhinosinusitis, CFTR-related metabolic syndrome (CRMS), pancreatitis, idiopathic chronic pancreatitis and Sjörgren's syndrome, or for use in preventing male infertility caused by congenital absence of the vas deferens, in a patient by modulating CFTR activity, which compound is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a leukotriene receptor antagonist. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a CFTR potentiator or a CFTR corrector. | 2021-04-15 |
20210106586 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE ASSOCIATED INFLAMMATION AND DISORDERS - Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one reverse transcriptase inhibitor (RTI). | 2021-04-15 |
20210106587 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY - Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein. | 2021-04-15 |
20210106588 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS - The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer. | 2021-04-15 |
20210106589 | SOLID DOSAGE FORM HAVING EXCELLENT STABILITY - The present invention provides a solid dosage form having good stability, suspensibility in water and fluidity by preparing a solid dosage form containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a stabilizer, a sugar alcohol and/or a sugar, a water-soluble polymer and an inorganic substance. | 2021-04-15 |
20210106590 | USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION - Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders. | 2021-04-15 |
20210106591 | MELOXICAM COMPOSITION, PREPARATION AND PREPARATION METHOD AND USE THEREOF - The disclosure is related to a meloxicam compositions, pharmaceutical preparations, preparation methods and use thereof. In one aspect of the invention, meloxicam compositions contain meloxicam and cosolvents. The cosolvents are mixed solvents including water and organic solvents. In another aspect of the invention, other compositions contain meloxicam, solvents, and pH regulators. The pH regulators include at least citric acid. The pharmaceutical compositions significantly enhance the solubility of meloxicam in liquid pharmaceutical preparations as well as stability. The meloxicam compositions can be directly used for intravenous injection administration to quickly reach effective therapeutic concentrations for post-operative analgesia. | 2021-04-15 |
20210106592 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI) AND RELATED DISORDERS - The present invention relates to methods for the treatment or prevention of symptoms associated with traumatic brain injury (TBI) and related disorders. The present disclosure provides compositions and methods for preventing or treating traumatic brain injuries and other neurological disorders arising from such an injury in a subject by administering to the subject an effective amount of a composition comprising opipramol. In certain embodiments, the present disclosure provides compositions and methods for treating traumatic brain injuries and other neurological disorders arising from such an injury in a subject by administering to the subject an effective amount of a composition comprising opipramol co-administered with additional agents or treatments. | 2021-04-15 |
20210106593 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein R | 2021-04-15 |
20210106594 | METHODS, COMPOSITIONS, AND KITS FOR TREATING AND/OR PREVENTING A SIDE EFFECT ASSOCIATED WITH RADIATION AND/OR CHEMOTHERAPY EXPOSURE - Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose. | 2021-04-15 |
20210106595 | THERAPEUTIC EFFECTS OF GUANABENZ TREATMENT IN VANISHING WHITE MATTER - The invention relates to Guanabenz or an analogue thereof for use in the treatment and to methods of treatment of a subject that has vanishing white matter (VWM), comprising administering the compound Guanabenz or an analogue thereof to the subject in need thereof. Also provided are methods with which the success of a medical intervention in a subject with VWM can be determined. Such methods comprise quantifying the translocation of Bergmann glia into the molecular layer in the cerebellum in a suitable sample of the subject. The sample is typically a post mortem sample. | 2021-04-15 |
20210106596 | 17-HYDROXYPROGESTERONE ESTER-CONTAINING ORAL COMPOSITIONS AND RELATED METHODS - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 2021-04-15 |
20210106597 | OTIC FORMULATIONS, METHODS AND DEVICES - The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and/or clotrimazole and dexamethasone. | 2021-04-15 |
20210106598 | PHYTATES FOR USE AS A BIOMOLECULES DELIVERY OR ADSORPTION SYSTEM - The present invention relates to mineral micro-particles comprising phytate (inositol hexaphosphate, IP6). More particularly, the invention provides salts of phytic acid with multivalent metal ions such as Ca | 2021-04-15 |
20210106599 | METHODS FOR IMPROVING THE GASTROINTESTINAL TOLERANCE OF FOOD AND BEVERAGE PRODUCTS COMPRISING SWEET, LOW-DIGESTIBLE CARBOHYDRATES - The present invention relates to methods for improving the gastrointestinal tolerance of food and beverage products comprising sweet, low-digestible carbohydrates, and the use of one or more of D-glucose, fiber and protein for improving the gastrointestinal tolerance of food and beverage products comprising sweet, low-digestible carbohydrates. | 2021-04-15 |
20210106600 | FLAVONOID COMPOSITIONS AND RELATED METHODS - Flavonoids that are isolated from plant material of the genus | 2021-04-15 |
20210106601 | MANGIFERIN AS A PROTECTIVE AGENT AGAINST MITOCHONDRIAL DNA DAMAGE AND SKIN-CARE COMPOSITIONS COMPRISING SAME - The invention relates to compounds that provide protective effects against mitochondrial DNA damage. In particular, it relates to mangiferin, ideally in the form of a naturally-occurring mangiferin extract, and to mangiferin-containing compositions and their use as protective agents against mitochondrial DNA damage. Aspects of the invention relate to an additive for a skin care composition, wherein the additive comprises a complex of mangiferin with β-cyclodextrin or a β-cyclodextrin derivative. The invention also relates to skin care compositions comprising the mangiferin complexes, as well as to methods of their preparation. In embodiments, the additive can be used in a sunscreen formulation to protect against UV-induced mtDNA damage. | 2021-04-15 |
20210106602 | INJECTABLE ANTIBIOTIC FORMULATIONS AND USE THEREOF - Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin and tulathromycin. In particular, compositions containing azithromycin or tulathromycin with low toxicity, especially for administration to canines, are provided herein. | 2021-04-15 |
20210106603 | INDUCTION OF SYNTHETIC LETHALITY WITH EPIGENETIC THERAPY - The disclosure generally relates to compositions and methods for the treatment of cancer. In some aspects, disclosed herein are methods for the induction of synthetic lethality with epigenetic therapy (ISLET) using a combination of at least one epigenetic compound and at least one chemotherapeutic agent. Also disclosed herein are screening methods for identifying compounds that induce killing of cancer cells when combined with at least one epigenetic compound. Further disclosed herein are methods of potentiating a therapeutic effect of a chemotherapeutic agent against a cancer, comprising administering to a subject having the cancer an epigenetic compound in an amount effective to potentiate the therapeutic effect of the chemotherapeutic agent against the cancer. | 2021-04-15 |
20210106604 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs. | 2021-04-15 |
20210106605 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders - The present invention relates to the use of adenosine receptor modulators to affect the circadian rhythm, in particular, to the use of such modulators for the treatment of circadian rhythm disorders. In particular, the invention relates to a composition comprising at least one selective adenosine receptor modulator, wherein said composition modulates two or three, but not all of adenosine receptor subtypes A | 2021-04-15 |
20210106606 | USE OF NAD PRECURSORS FOR IMPROVING MATERNAL HEALTH AND/OR OFFSPRING HEALTH - Certain embodiments of the invention provide a method for improving maternal and/or offspring health, comprising administering an effective amount of a nicotinamide adenine dinucleotide (NAD) precursor to a female mammal (e.g., pregnant or lactating female mammal). | 2021-04-15 |
20210106607 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE - The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. | 2021-04-15 |
20210106608 | Morpholino Oligonucleotides Useful In Cancer Treatment - Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides. | 2021-04-15 |
20210106609 | HEALTH SUPPLEMENT - A kit for supporting health of a user throughout the user's menstrual cycle may include at least two daily supplements of a first type, and at least two daily supplements of a second type, the second type different from the first type, wherein the daily supplements of the first type and the daily supplements of the second type are packaged in a single kit according to menstrual cycle phase. A method for supporting health of a user throughout the user's menstrual cycle may include providing at least two daily supplements of a first type, providing at least two daily supplements of a second type, and instructing the user to ingest the daily supplements of the first type during at least two days of a first time period of the menstrual cycle, and to ingest the daily supplements of the second type during at least two days of a second time period of the menstrual cycle. | 2021-04-15 |
20210106610 | POLYSACCHARIDES FOR THE TREATMENT OF OCULAR CONDITIONS - The use of a polysaccharide derived from a bacterial strain in the prevention of ocular diseases and the treatment of ocular diseases. Especially, the ophthalmic use of a polysaccharide susceptible to be obtained from the CNCM I-5038 | 2021-04-15 |
20210106611 | METHOD OF TREATING ACID-BASE DISORDERS - The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human. In certain embodiments, compositions for and methods of improving the quality of life and/or physical function score of such patients are also provided. In certain embodiments, compositions for and methods of slowing the progression of kidney disease in such patients are also provided. | 2021-04-15 |
20210106612 | TARGET GENE TRANSCRIPTIONAL REPRESSION INHIBITOR THAT CAN BE DESIGNED IN A SEQUENCE-SPECIFIC MANNER, COMPOSITION CONTAINING SAME, AND USE THEREOF - The present invention provides a target gene transcriptional repression inhibitor that can be designed in a sequence-specific manner, a composition containing the same, and use thereof. More specifically, the present invention provides a composition for use in inhibiting repression of gene expression by DNA methylation in a living subject, comprising pyrrole imidazole polyamide or a conjugate of pyrrole imidazole polyamide and a histone modifying enzyme inhibitor, wherein the pyrrole imidazole polyamide or the conjugate of pyrrole imidazole polyamide and a histone modifying enzyme inhibitor is designed so as to bind in a sequence-specific manner to a minor groove of promoter region DNA of the gene. | 2021-04-15 |
20210106613 | BROMIDE SOURCE FOR USE IN TREATING AUTISM SPECTRAL DISORDER - The present invention relates to a novel pharmaceutical use of bromide, i.e. the treatment of autism spectral disorder (ASD). | 2021-04-15 |
20210106614 | METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES - The invention relates to method of treating chronic inflammatory diseases in subjects in need thereof by administering calcium lactate as an active agent. The calcium lactate can be provided in a pharmaceutical, food, or nutrient composition. | 2021-04-15 |
20210106615 | NANOPARTICLE, PREPARATION PROCESS AND USES THEREOF - The present disclosure provides a nanoparticle, a preparation process thereof, a method for treating cancer, a method for enhancing effect of a liver cancer drug, a method for ameliorating tumor hypoxia, and a method for enhancing effect of a liver cancer vaccine by using the nanoparticle. | 2021-04-15 |
20210106616 | Use of Plasma and Plasma Fractions for Improvement of Pain, Wound Healing, and Postoperative Recovery - Methods and compositions for improving postoperative recovery are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing conditions associated with postoperative recovery. | 2021-04-15 |
20210106617 | COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT - Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, methods of treating a cancer or tumor, methods of reducing tumor load, methods of reducing the size or growth rate of a cancer or a tumor, and methods of extending of the survival of a subject suffering from a cancer or tumor, wherein the subjects are administered compositions comprising apoptotic cells or apoptotic cell supernatants. Compositions and methods of use thereof may increase the efficacy of a CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm. In certain instances compositions may include additional chemotherapeutic or immunomodulatory agents. | 2021-04-15 |
20210106618 | METHODS FOR IMPROVING ADOPTIVE CELL THERAPY - The present disclosure provides reagents and methods for treating disease using modified immune cells (e.g., T cell comprising CAR or TCR) in combination with an agent associated with induction of immunogenic cell death (ICD) and optionally further in combination with an agent that specifically binds to and/or inhibits an immune suppression component and/or an agonist of an immune stimulatory molecule. | 2021-04-15 |
20210106619 | NK-92 Bone and Brain targeting - Compositions of luminescence labeled activated natural killer (aNK) cells are utilized in methods of in vivo bioluminescence imaging (BLI) for assaying and identifying genetically modified NK cells capable of targeting selected anatomical locations (e.g., bone and/or brain) or targeting selected diseased cells at selected sites. | 2021-04-15 |
20210106620 | METHOD FOR PROMOTING IMMUNE CELL PROLIFERATION - Disclosed is a method for promoting immune cell proliferation. The method comprises the following step: upregulating the expression of low-density lipoprotein receptor-related proteins or fragments thereof in immune cells. | 2021-04-15 |
20210106621 | METHOD OF TREATING IMMUNOTHERAPY NON-RESPONDERS WITH AN AUTOLOGOUS CELL THERAPY - Methods of treating cancer in Non-Responder Patients with an engineered NeoTCR Product are described herein. | 2021-04-15 |
20210106622 | TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS - The present invention regards methods and/or compositions related to Natural Killer T cells that are engineered to harbor an expression construct that encodes IL-2, IL-4, IL-7, and/or IL-15 and additionally or alternatively comprise a chimeric antigen receptor (CAR). In specific embodiments, the CAR is a CAR that targets the GD2 antigen, for example in neuroblastoma. | 2021-04-15 |
20210106623 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-04-15 |
20210106624 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST EPITHELIAL OVARIAN CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-04-15 |